Photo by sammoqadam from unsplash
Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality, consuming a significant proportion of public health spending. Following lifestyle changes, the most common treatment for… Click to show full abstract
Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality, consuming a significant proportion of public health spending. Following lifestyle changes, the most common treatment for T2D is the addition of oral hypoglycemic agents with broader selection for patients over the time. This summary is based on a lecture given 6 June 2020 at the Eighth Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy AP), reexamining the characteristics of the older hypoglycemic agents, including metformin, dipeptidyl peptidase (DPP)-4 inhibitors, sulfonylureas (SUs), thiazolidinediones (TZDs), acarbose, colesevelam, and bromocriptine.
Journal Title: Journal of Diabetes
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!